MeSH D002295 - transitional cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Astellas Pharma | Enfortumab vedotin | Padcev |  | 2022-04-13 |  |  |
| AstraZeneca | Durvalumab | Imfinzi |  | 2017-05-01 | $2,558 M | Q2/21-Q2/24 |
| Bristol Myers Squibb | Nivolumab | Opdivo |  | 2015-06-19 | $9,127 M | Q3/23-Q2/24 |
| EMD Serono | Avelumab | Bavencio |  | 2017-03-23 |  |  |
| Johnson & Johnson | Erdafitinib | Balversa | 2031-04-28 | 2019-04-12 |  |  |
| Laboratoires Pierre Fabre | Vinflunine | Javlor |  | 2009-09-21 |  |  |
| Merck & Co | Avelumab | Bavencio |  | 2017-09-18 |  |  |
| Pembrolizumab | Keytruda |  | 2015-07-17 | $27,162 M | Q3/23-Q2/24 | |
| Roche | Atezolizumab | Tecentriq |  | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 |
Clinical Trials
Historical Success Rate
Phase 1
65%15/23
Phase 2
29%15/52
Phase 3
35%11/31
Approved: 9Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use